Caribou Biosciences, Inc. (CRBU)

NASDAQ: CRBU · IEX Real-Time Price · USD
11.61
-0.02 (-0.17%)
At close: Jan 14, 2022 4:00 PM
11.87
0.26 (2.24%)
After-hours:Jan 14, 2022 7:59 PM EST
Market Cap698.83M
Revenue (ttm)n/a
Net Income (ttm)-63.15M
Shares Out60.19M
EPS (ttm)-3.37
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume614,799
Open11.49
Previous Close11.63
Day's Range10.82 - 11.75
52-Week Range10.82 - 32.65
Betan/a
AnalystsStrong Buy
Price Target31.20 (+168.7%)
Earnings Daten/a

About CRBU

Caribou Biosciences is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying our novel CRISPR platform, chRDNA toward the development of next-generation, genome-edited cell therapies. We believe that our technology has broad potential to generate gene and cell therapies in oncology and in therapeutic areas beyond oncology, including immune cell therapies, cell therapies derived from genome-edited iPSCs, and in vivo genome-editing therapies. We are initially focused on ad...

IndustryBiotechnology
IPO DateJul 23, 2021
CEORachel E. Haurwitz, Ph.D.
Employees66
Stock ExchangeNASDAQ
Ticker SymbolCRBU
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for CRBU stock is "Strong Buy." The 12-month stock price forecast is 31.20, which is an increase of 168.73% from the latest price.

Price Target
$31.20
(168.73% upside)
Analyst Consensus: Strong Buy

News

Caribou Biosciences to Present at 40th Annual J.P. Morgan Healthcare Conference

BERKELEY, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that Rachel Haurwit...

1 week ago - GlobeNewsWire

Caribou Biosciences to Present at Upcoming Investor Conferences

BERKELEY, Calif., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that Rachel Haurwit...

1 month ago - GlobeNewsWire

Caribou Biosciences Provides Business Update and Reports Third Quarter 2021 Financial Results

On track to achieve key milestones, including plan to disclose initial clinical data in 2022 for lead product candidate CB-010

2 months ago - GlobeNewsWire

Caribou Biosciences Appoints Biotechnology Industry Veteran Ran Zheng to its Board of Directors

BERKELEY, Calif., Sept. 29, 2021 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today it has appointed R...

3 months ago - GlobeNewsWire

Caribou Biosciences to Participate in the Chardan Virtual 5th Annual Genetic Medicines Conference

BERKELEY, Calif., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that Rachel Haurwi...

3 months ago - GlobeNewsWire

Caribou Biosciences Provides Business Update and Reports Second Quarter 2021 Financial Results

Completed upsized initial public offering of common stock, raising $349.6 million in gross proceeds including full exercise of underwriters' option to purchase additional shares

4 months ago - GlobeNewsWire

Caribou Biosciences Announces Publication of Data Demonstrating High Specificity Genome Editing with its Proprietary ...

Data published in Molecular Cell provide a mechanistic framework to explain the enhanced specificity and key differentiation of Caribou's proprietary chRDNA technology for therapeutic applications

4 months ago - GlobeNewsWire

Caribou Biosciences Appoints Nancy Whiting, Pharm.D., to its Board of Directors

BERKELEY, Calif., Aug. 25, 2021 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that it has appoin...

4 months ago - GlobeNewsWire

Caribou Biosciences Announces Closing of Upsized Initial Public Offering

BERKELEY, Calif.--(BUSINESS WIRE)---- $CRBU--Caribou Biosciences, Inc., (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today the closing of its previ...

5 months ago - Business Wire

3 Reasons Caribou Biosciences Could Be the Best Gene-Editing Stock for Your Portfolio

The company has a pedigree and a novel approach that could put it at the top of the CRISPR heap.

5 months ago - The Motley Fool

Caribou Biosciences Announces Pricing of Upsized Initial Public Offering

BERKELEY, Calif.--(BUSINESS WIRE)--Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today the pricing of its upsized initial public offering...

5 months ago - Business Wire

Caribou Biosciences Announces Dosing of First Patient in Phase 1 Clinical Trial Evaluating CB-010, a CRISPR-Edited Al...

BERKELEY, Calif.--(BUSINESS WIRE)--Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that the first patient has been dosed in its open-...

6 months ago - Business Wire

Caribou Biosciences Eyes $100M NASDAQ Debut To Propel Off-The-Shelf CAR-T Therapies In Blood Cancer

In a filing with SEC on Thursday, Caribou Biosciences (NASDAQ: CRBU) is penciling in a $100 million initial public offering. The firm expects that its new shares will trade on the NASDAQ under the symbo...

6 months ago - Benzinga